230
Participants
Start Date
December 31, 2025
Primary Completion Date
January 1, 2031
Study Completion Date
March 31, 2035
Magnesiocard
2.5 mmol film-coated tablets in addition to standard first line therapy
Magnesium Diasporal
4 mmol IV formulation in addition to standard first line therapy
Microcrystalline cellulose
Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy
Isotonic saline solution 0.9%
Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy
Spital STS AG, Thun
St. Claraspital, Basel
Universitätsspital Basel, Basel
Kantonsspital Olten, Olten
Tumorzentrum Aarau - Hirslanden TZA, Aarau
Kantonsspital Baden, Baden
Luzerner Kantonsspital, Lucerne
Kantonsspital Winterthur, Winterthur
Kantonsspital Aarau, Aarau
Kantonsspital Graubuenden, Chur
Kantonsspital - St. Gallen, Sankt Gallen
Swiss Cancer Institute
OTHER